---
title: "bioAffinity Technologies, Inc. (BIAF.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BIAF.US.md"
symbol: "BIAF.US"
name: "bioAffinity Technologies, Inc."
industry: "Biotechnology"
datetime: "2026-05-01T07:15:22.213Z"
locales:
  - [en](https://longbridge.com/en/quote/BIAF.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BIAF.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BIAF.US.md)
---

# bioAffinity Technologies, Inc. (BIAF.US)

## Company Overview

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [bioaffinitytech.com](https://bioaffinitytech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-30T04:30:17.000Z

**Overall: C (0.59)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 189 / 389 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -34.18% |  |
| Net Profit YoY | -64.93% |  |
| P/B Ratio | 1.50 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10931780.25 |  |
| Revenue | 6161959.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -301.83% | E |
| Profit Margin | -241.96% | E |
| Gross Margin | 31.40% | C |
| Revenue YoY | -34.18% | E |
| Net Profit YoY | -64.93% | E |
| Total Assets YoY | 68.27% | A |
| Net Assets YoY | 179.69% | A |
| Cash Flow Margin | 62.57% | C |
| OCF YoY | -34.18% | E |
| Turnover | 0.71 | B |
| Gearing Ratio | 33.60% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - bioAffinity Technologies, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-34.18%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.93%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.50",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10931780.25",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "6161959.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-301.83%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-241.96%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "31.40%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-34.18%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.93%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "68.27%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "179.69%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "62.57%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-34.18%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.71",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.60%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.75 | 166/389 | - | - | - |
| PB | 1.54 | 141/389 | 5.40 | 1.50 | 0.62 |
| PS (TTM) | 1.81 | 48/389 | 1.27 | 0.91 | 0.71 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | C | A |

## Institutional View

### Analyst Rating Distribution

> As of 2025-08-21T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.48 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BIAF.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BIAF.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BIAF.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BIAF.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**